Drug Trial Radar · NCT07839871
Study to Learn About a Respiratory Syncytial Virus Vaccine in Children at High Risk of RSV Disease
Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
920
Planned (sponsor's estimate)
Start
Sep 22, 2026
Primary completion
Mar 30, 2031
Study completion Mar 30, 2031
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Sep 24, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 5 years, up to 17 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the safety, tolerability, and immunogenicity of RSVpreF in children 5 to \<18 years of age at high risk for RSV disease, including those who are immunocompromised.
Conditions
- Respiratory Syncytial Virus (RSV)
Interventions
RSVpreFBiological
RSVpreF Vaccine
PlaceboBiological
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cohort 1: Proportion of participants reporting pre-specified local reactions within 7 days following investigational product administrationTime frame: Within 7 days
- Cohort 2: Proportion of participants reporting pre-specified local reactions within 7 days following each investigational product administrationTime frame: Within 7 days
- Cohort 1: Proportion of participants reporting pre-specified systemic events within 7 days following investigational product administrationTime frame: Within 7 days
- Cohort 2: Proportion of participants reporting pre-specified systemic events within 7 days following each investigational product administrationTime frame: Within 7 days
- Cohort 1: Proportion of participants reporting adverse events (AEs) through 1 month following investigational product administrationTime frame: From vaccination through 1 month after vaccination
- Cohort 2: Proportion of participants reporting adverse events (AEs) through 1 month following last investigational product administrationTime frame: From vaccination through 1 month after last vaccination
- Cohort 1: Proportion of participants reporting serious adverse events (SAEs) throughout the studyTime frame: From vaccination through 24 months after vaccination
- Cohort 2: Proportion of participants reporting serious adverse events (SAEs) throughout the studyTime frame: From vaccination through 12 months after last vaccination
- Cohort 1: Proportion of participants reporting newly diagnosed chronic medical conditions (NDCMCs) throughout the studyTime frame: From vaccination through 24 months after vaccination
- Cohort 2: Proportion of participants reporting newly diagnosed chronic medical conditions (NDCMCs) throughout the studyTime frame: From vaccination through 12 months after last vaccination
- Cohort 1: Geometric mean ratio (GMR), estimated by the ratio of the geometric mean titers (GMTs) for RSV A and RSV B serum neutralizing titers (NTs) 1 month after vaccination in participants in Study C3671017 Cohort 1 compared to those in Study C3671013Time frame: 1 month after vaccination
- Cohort 1: Seroresponse rate of RSV A and RSV B serum NTs at 1 month after vaccinationTime frame: 1 month after vaccination
- Cohort 2: Neutralizing Titers (NTs) for RSV A and RSV B expressed as Geometric Mean Titers (GMT)Time frame: Before each vaccination, 1 month after each vaccination, 12 months after last vaccination
- Cohort 2: NTs for RSV A and RSV B expressed as Geometric Mean Fold Rise (GMFR)Time frame: 1 month after each vaccination, 12 months after last vaccination
- Cohort 2: NTs for RSV A and RSV B expressed as seroresponse rateTime frame: 1 month after each vaccination, 12 months after last vaccination
Locations
20 sites in 4 countries. Site status is shown where the registry gives one.
Duke Vaccine and Trials Unit
Durham, North Carolina · Recruiting
Cincinnati Children's Hospital Medical Center Vaccine Research Center
Cincinnati, Ohio · Recruiting
Senders Pediatrics
South Euclid, Ohio · Recruiting
Seattle Childrens Research Institute
Seattle, Washington · Recruiting
Seattle Children's Hospital
Seattle, Washington · Recruiting
Maebashi Red Cross Hospital
Maebashi, Gunma, Japan · Recruiting
Saitama City Hospital
Midori, Saitama, Japan · Recruiting
Fukuwa Clinic
Chuo-ku, Tokyo, Japan · Recruiting
Uniwersytecki Dziecięcy Szpital Kliniczny im. L. Zamenhofa w Białymstoku
Bialystok, Poland · Not yet recruiting
IN-VIVO Bydgoszcz
Bydgoszcz, Poland · Not yet recruiting
Samodzielny Zespół Publiczny Zakładów Opieki Zdrowotnej im. Dzieci Warszawy w Dziekanowie Leśnym
Dziekanów Leśny, Poland · Recruiting
Pro Familia Altera Sp. z o.o.
Katowice, Poland · Not yet recruiting
Centrum Badań Klinicznych - Jagiellońskie Centrum Innowacji Sp. z o.o.
Krakow, Poland · Recruiting
ALERGO-MED Osrodek Badan Klinicznych Sp z o.o.
Tarnów, Poland · Not yet recruiting
Szpital im.Sw.Jadwigi Slaskiej w Trzebnicy
Trzebnica, Poland · Not yet recruiting
ZOZ Medyk Sp. z o.o.
Milówka, Silesian Voivodeship, Poland · Not yet recruiting
Servicio Andaluz de Salud (SAS) - Hospital de Antequera
Antequera, Spain · Not yet recruiting
Hospital Universitario HM Puerta del Sur
Móstoles, Spain · Not yet recruiting
Instituto Hispalense de Pediatria
Seville, Spain · Not yet recruiting
Hospital Universitario La Paz
Madrid, Madrid, Comunidad de, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.